Clinical trials: Conflict Resolution
Allergic Conjunctivitis
Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model
The purpose of this study is to evaluate the efficacy of different concentrations of AC-170 compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- AC-170 (NCT01332188)
- Testing
- AC-170 0.05%, AC-170 0.1%, AC-170 0.24%
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Aciex Therapeutics, Inc.
Parkinson's Disease
A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients
A cross-over study, where ND0611 or placebo will be tested on top of 3 different LD/CD dosage forms. Safety and tolerability, pharmacokinetic profile of levodopa and carbidopa and the potential clinical effect of ND0611 will be…
- Trial name
- NCT01229332
- Testing
- Saline, Carbidopa
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- NeuroDerm Ltd.
Healthy
A Study of Two Different Formulations of LY3209590 in Healthy Participants
The main purpose of this study is to look at the amount of the study drug, LY3209590, that gets into the blood stream and how long it takes the body to get rid of LY3209590 when given as different formulations.
- Trial name
- NCT04768842
- Testing
- LY3209590
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Two Different Formulations of LY3074828 in Healthy Participants
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations.
- Trial name
- NCT03188510
- Testing
- LY3074828
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
The main objectives of the SRD part of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 1356225 in healthy male subjects following oral administration of single rising…
- Trial name
- NCT04065295
- Testing
- BI 1356225
- Where
- Germany
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma
Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.
Rationale for the current trial is to evaluate the efficacy and safety of three doses (1.25 µg, 2.5 µg and 5.0 µg ex mouthpiece) of tiotropium inhalation solution in patients with moderate persistent asthma who are still…
- Trial name
- NCT01233284
- Testing
- tiotropium bromide 2.5µg once daily, tiotropium bromide high dose once daily, tiotropium bromide 1.25µg once daily
- Where
- 19 sites in Austria, Germany and 1 more
- Volunteers
- 149 people
- Sponsor
- Boehringer Ingelheim
Dry Eye Disease
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
Primary objective To evaluate the efficacy of 5 μg/mL and 10 μg/mL concentrations of the new formulation of rhNGF ophthalmic solution versus vehicle, in order to demonstrate superiority of at least 1 of the concentrations over…
- Trial name
- REDUCO (NCT06244316)
- Testing
- rhNGF 5 μg/mL, rhNGF 10 μg/mL
- Where
- 14 sites in United States, Italy
- Volunteers
- 317 people
- Sponsor
- Dompé Farmaceutici S.p.A
Hypogonadism
A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations
Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product- Testosterone MD-Lotion (cutaneous solution), and this study will evaluate the…
- Trial name
- NCT00702650
- Testing
- Testosterone MD-Lotion
- Where
- 27 sites in United States, Australia and 4 more
- Volunteers
- 155 people
- Sponsor
- Eli Lilly and Company
Peripheral Vascular Disease
Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers
Unifusol (R) is a solution of arginine sodium succinate for intravenous infusions. Its effects include vasodilation, protection of inner layer of blood vessels and improvement of blood viscosity.
- Trial name
- NCT03028285
- Testing
- arginine sodium succinate
- Where
- 2 sites in Russia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Bacterial Conjunctivitis
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
A randomized, double blind, phase II multicenter trial with the objective of assess the safety and efficacy of the PRO-157 ophthalmic solution in three different dosing regimens, versus Moxifloxacin, versus Gatifloxacin in…
- Trial name
- Pazufloxacin (NCT02980523)
- Testing
- PRO-157, Vigamox, Zymar®
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
The purpose of this study is to determine whether SAR 1118 at three different concentrations, compared to placebo, is effective in the prevention of the signs and symptoms of allergic conjunctivitis
- Trial name
- NCT00882687
- Testing
- Lifitegrast
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shire
Dry Eye
Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Phase II, comparative, controlled, multicenter, parallel group, open, randomized clinical study. The main outcome variable will be the Ocular Surface Disease Index (OSDI) questionnaire.
- Trial name
- PRO-037 (NCT04704531)
- Testing
- Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day
- Where
- Mexico
- Volunteers
- 141 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma, Ocular Hypertension
Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of bimatoprost 0.03% formulation B ophthalmic solution with LUMIGAN® (bimatoprost ophthalmic solution 0.03%) once daily for 12 weeks in patients with glaucoma or ocular hypertension
- Trial name
- NCT01099774
- Testing
- Bimatoprost 0.03% Formulation B Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution
- Where
- United States
- Volunteers
- 597 people
- Sponsor
- Allergan
Acanthamoeba Keratitis
Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
Randomized, double-masked, placebo-controlled, multiple center, parallel-group Phase 1 study to evaluate the safety and tolerability of 3 doses of preservative-free PHMB ophthalmic solution compared to placebo in healthy subjects
- Trial name
- NCT02506257
- Testing
- 0.04% PHMB, 0.06% PHMB, 0.08% PHMB
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- SIFI SpA
Healthy
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
Primary objective mass balance, excretion pathways and metabolism following a single oral dose of [14C]BI 1467335 given to healthy male subjects (a selected number of subjects will be treated with [14C]BI 1467335 after a…
- Trial name
- NCT03382509
- Testing
- [14C]BI 1467335, BI 1467335
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers
To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration.
- Trial name
- NCT02244190
- Testing
- Tipranavir, Ritonavir
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution
This study is a Phase I, randomized, open-label, cross-over study with 4 single-dose treatments of GLPG1972 to compare the bioavailability of the oral wet granulation (WG) tablet relative to an oral solution and to the oral…
- Trial name
- NCT03143725
- Testing
- GLPG1972
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Psoriasis Vulgaris
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis
To assess safety and tolerability after treatment with LEO 134310 cutaneous solution.
- Trial name
- NCT03669757
- Testing
- LEO 134310, LEO 134310 vehicle, 0.1% betamethasone valerate ointment (class III steroid)
- Where
- 2 sites in Germany
- Volunteers
- 13 people
- Sponsor
- LEO Pharma
Burns
ST266 Versus Standard Care In Treating Partial Thickness Burns
The objective of this protocol is to perform a safety and dose-determination efficacy clinical trial in patients having a degree of partial-thickness burn wounds.
- Trial name
- NCT00886470
- Testing
- ST266
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Healthy
A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without Food
Single-rising dose (SRD) part The main objectives of the SRD part of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1815368 in healthy male subjects following oral administration of single…
- Trial name
- NCT05337592
- Testing
- BI 1815368 formulation 1, BI 1815368 formulation 2
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim